Critical Reappraisal of Obinutuzumab Randomized Trials in Membranous Nephropathy Authors: Piero Ruggenenti, Matias Trillini, Manuel Alfredo Podestà, Giuseppe Remuzzi Published: 2026 To the Editor: We read with interest the commentary to our work by Giri et al.,1 and particularly their reference to the MAJESTY trial and its potential implications for the evolving therapeutic landscape of primary membranous nephropathy (MN). MAJESTY is a randomized controlled trial comparing the anti-CD20 monoclonal antibody obinutuzumab with tacrolimus as a first-line therapy in 142 patients with MN and nephrotic syndrome. This study was registered well after the MENTOR trial results had already been reported.2 Data from the MENTOR trial provided clear-cut evidence of rituximab superiority over cyclosporine in patients with MN. Based on these findings, the Kidney Disease: Improving Global Outcomes 2021 guidelines recommend rituximab as a first-line therapy for patients with MN at high risk of progression, whereas calcineurin inhibitor monotherapy is not recommended.3 Rituximab should therefore be considered as the reference comparator for any novel therapy evaluated in this population, and it remains unclear why participants in the MAJESTY trial control group received tacrolimus monotherapy rather than a rituximab-based standard-of-care regimen. Similar considerations apply to the BEGIN trial, which compares obinutuzumab with cyclosporine monotherapy in 155 participants with MN. Conceivably, results from these trials will provide the basis to support obinutuzumab approval as first-line therapy in MN, rather than just for rescue therapy after rituximab failure.4 This could have important implications for healthcare providers, as treatment with obinutuzumab according to MAJESTY schedule (1 g x 4) would cost nearly €7000, compared with approximately €2000 for rituximab administered according to the MENTOR regimen (1 g × 2). Moreover, the cost of rituximab could be reduced by up to 4-fold when a B-cell driven protocol is adopted,5 and may decrease by a further ∼ 50% with the use of rituximab biosimilars. It is essential that academic medicine maintains a critical perspective in interpreting the findings of these trials, which may pave the way for future studies comparing the overall cost-benefit profile of obinutuzumab versus rituximab as first-line therapy. Ultimately, rigorous trial design and careful interpretation will be essential to ensure that new therapeutic options for MN are adopted on the basis of clear clinical and economic value. Disclosures All the authors declared no competing interests.